Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers

Purpose: To identify novel endometrial cancer-specific methylation markers and to determine their association with clinicopathologic variables and survival outcomes. Experimental Design: Differential methylation hybridization analysis (DMH) was done for 20 endometrioid endometrial cancers using normal endometrial DNA as a reference control. Combined bisulfite restriction analysis (COBRA) was used to verify methylation of sequences identified by DMH. Bisulfite sequencing was undertaken to further define CpG island methylation and to confirm the reliability of the COBRA. The methylation status of newly identified markers and the MLH1 promoter was evaluated by COBRA in a large series of endometrioid (n = 361) and non-endometrioid uterine cancers (n = 23). Results: DMH and COBRA identified two CpG islands methylated in tumors but not in normal DNAs: SESN3 (PY2B4) and TITF1 (SC77F6/154). Bisulfite sequencing showed dense methylation of the CpG islands and confirmed the COBRA assays. SESN3 and TITF1 were methylated in 20% and 70% of endometrioid tumors, respectively. MLH1 methylation was seen in 28% of the tumors. TITF1 and SESN3 methylation was highly associated with MLH1 methylation (P < 0.0001). SESN3 and TITF1 were methylated in endometrioid and non-endometrioid tumors, whereas MLH1 methylation was restricted to endometrioid tumors. Methylation at these markers was not associated with survival outcomes. Conclusions: The 5′ CpG islands for SESN3 and TITF1 are novel cancer-specific methylation markers. Methylation at these loci is strongly associated with aberrant MLH1 methylation in endometrial cancers. SESN3, TITF1 and MLH1 methylation did not predict overall survival or disease-free survival in this large cohort of patients with endometrioid endometrial cancer.

[1]  R K Gordon,et al.  S‐Adenosylmetliionine and methylation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Terry L. Smith,et al.  DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Y. Yatabe,et al.  TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.

[4]  D. Sidransky,et al.  Molecular detection approaches for smoking associated tumors , 2002, Oncogene.

[5]  J. Ajani,et al.  Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Palazzo,et al.  MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. , 1999, Human molecular genetics.

[7]  P. Goodfellow,et al.  Ribosomal DNA methylation in patients with endometrial carcinoma , 2002, Cancer.

[8]  Peter A. Jones,et al.  Cell division is required for de novo methylation of CpG islands in bladder cancer cells. , 2002, Cancer research.

[9]  P. Goodfellow,et al.  Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  C. M. Chen,et al.  Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. , 2001, Cancer research.

[12]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[13]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[14]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[15]  R. Lauro,et al.  The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. , 1991, Development.

[16]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[17]  M. Polak,et al.  PAX8, TITF1, and FOXE1 gene expression patterns during human development: new insights into human thyroid development and thyroid dysgenesis-associated malformations. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  H. Peeters,et al.  PA26 is a candidate gene for heterotaxia in humans: identification of a novel PA26-related gene family in human and mouse , 2003, Human Genetics.

[19]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[20]  P. Laird,et al.  COBRA: a sensitive and quantitative DNA methylation assay. , 1997, Nucleic acids research.

[21]  H. Hermeking,et al.  Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation , 2005, Modern Pathology.

[22]  A. Kaneda,et al.  CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. , 2005, Cancer research.

[23]  P. Goodfellow,et al.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Ngan,et al.  Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. , 2005, The Journal of molecular diagnostics : JMD.

[25]  Jacqueline A. Hall,et al.  CpG island methylation of DNA damage response genes in advanced ovarian cancer. , 2005, Cancer research.

[26]  S. Tavaré,et al.  Counting human somatic cell replications: methylation mirrors endometrial stem cell divisions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R H Hruban,et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.

[28]  S. Merajver,et al.  Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. , 1996, The American journal of pathology.

[29]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[30]  Jan-Gowth Chang,et al.  Abnormal expression of period 1 (PER1) in endometrial carcinoma , 2005, The Journal of pathology.

[31]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[32]  M. Widschwendter,et al.  Methylated DNA collected by tampons--a new tool to detect endometrial cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  R. Broaddus,et al.  Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. , 2006, Cancer research.

[34]  Tsuyoshi Saito,et al.  Hypermethylation in promoter region of retinoic acid receptor-beta gene and immunohistochemical findings on retinoic acid receptors in carcinogenesis of endometrium. , 2005, Cancer letters.

[35]  Robert A. Waterland,et al.  Transposable Elements: Targets for Early Nutritional Effects on Epigenetic Gene Regulation , 2003, Molecular and Cellular Biology.

[36]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[37]  P. Goodfellow,et al.  Evidence for heritable predisposition to epigenetic silencing of MLH1 , 2007, International journal of cancer.

[38]  M. Toyota,et al.  Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein–Barr virus , 2006, Cancer.

[39]  V. Colot,et al.  Eukaryotic DNA methylation as an evolutionary device , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  M. Toyota,et al.  Screening for genomic fragments that are methylated specifically in colorectal carcinoma with a methylated MLH1 promoter. , 2005, Carcinogenesis.

[41]  M. Toyota,et al.  Methylation profiling in acute myeloid leukemia. , 2001, Blood.

[42]  M. de Felice,et al.  Thyroid development and its disorders: genetics and molecular mechanisms. , 2004, Endocrine reviews.

[43]  Manel Esteller,et al.  MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas , 1998, Oncogene.

[44]  S. Cross,et al.  Isolation of CpG islands from large genomic clones. , 1999, Nucleic acids research.

[45]  Nita Ahuja,et al.  DNA methylation and environmental exposures in human hepatocellular carcinoma. , 2002, Journal of the National Cancer Institute.

[46]  P. Catalano,et al.  Phenotype of Microsatellite-Stable Colorectal Carcinomas With CpG Island Methylation , 2005, The American journal of surgical pathology.

[47]  茂木 大子,et al.  Increasing 14-3-3 sigma expression with declining estrogen receptor α and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma , 2006 .

[48]  Leonard Buckbinder,et al.  PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes , 1999, Oncogene.